Intracameral Bevacizumab Versus Sub-Tenon’s Mitomycin C as Adjuncts to Trabeculectomy: 3-Year Results of a Prospective Randomized Study

Kopsinis, Gerasimos; Tsoukanas, Dimitrios; Kopsini, Dimitra; Filippopoulos, Theodoros

doi:10.3390/jcm10102054

Cited by 9 publications

(7 citation statements)

References 24 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[17][18][19] Despite bevacizumab been an efficient medication in controlling intraocular pressure the literature still reports that its efficacy is slightly lower than of mitomycin C in cases where both of the mediation are compared. 12,20 Similar results have been reported in the present study.…”

Section: Discussionsupporting

confidence: 92%

Intraocular Pressure Control after Trabeculectomy: A Comparison of Mitomycin C and Bevacizumab

Khan¹,

Siddiqui²,

Raza³

et al. 2022

PJMHS

View full text Add to dashboard Cite

Objective: To analyze and compare the role of mitomycin C and bevacizumab in reducing the intraocular pressure post trabeculectomy. Study Design: Comparative analytical study Place and Duration of Study: Department of Ophthalmology, Indus Medical College, Tando Mohammad Khan from 1st October 2021 to 31st March 2022. Methodology: Sixty patients were enrolled. Patients were divided equally in two groups. Thirty patients were given mitomycin C in Group A while Group B were those 30 patients who were given bevacizumab in a randomized manner. All the cases underwent trabeculectomy and followed upto a year and results were compared. An examination using slit lamp biomicroscope was performed for thorough examination of anterior segments with intraocular pressure recording. Gonioscopy through Goldman-two mirror lens was conducted. Results: The mean age of the patients was 50.23±7.7 years with 41.6 % females and 58.3% males. The intraocular pressure was seen to be controlled in 23 patients at day 1 in Group A and 23 patients in group B. The comparative analysis of pre and post intraocular pressure after trabeculectomy has presented the significant reduction in Group A than Group B at day 1, 6th week as well as at 3rd month or 6th moth to a year. Conclusion: Mitomycin C as well as bevacizumab are highly effective in reducing intraocular pressure post trabeculectomy with mitomycin C being slightly better in efficacy than bevacizumab. Keywords: Intraocular pressure, Trabeculectomy, Effective, Efficacy

show abstract

Section: Discussionsupporting

confidence: 92%

Intraocular Pressure Control after Trabeculectomy: A Comparison of Mitomycin C and Bevacizumab

Khan¹,

Siddiqui²,

Raza³

et al. 2022

PJMHS

View full text Add to dashboard Cite

show abstract

“…They concluded that average IOP and glaucoma medications decreased significantly in both groups at all follow-up points compared to baseline (p < 0.001), without significant difference between groups at 3 years. 20 Bilgic et al, compared the outcomes of trabeculectomy using two different routes of Bevacizumab administration as an adjunct in patients with primary open angle glaucoma. A significant reduction was observed in the IOP post trabeculectomy in all patients in both groups (paired t-test, P < 0.001, both groups), a change that had persisted at one-year follow-up.…”

Section: Kopsinis Et Al Compared the Effects Of Intracameralmentioning

confidence: 99%

Intraocular Pressure Control after Trabeculectomy with Adjunctive Use of Mitomycin-C versus Bevacizumab: A Hospital Based Study

et al. 2021

View full text Add to dashboard Cite

Purpose: To compare the control of intra ocular pressure (IOP) after trabeculectomy with adjunctive use of Mitomycin–C (MMC) versus Bevacizumab. Study Design: Quasi experimental study. Place and Duration of Study: Al-Ibrahim Eye Hospital, Isra Postgraduate Institute of Ophthalmology, Karachi, from August 2017 to August 2019. Methods: One hundred and six patients of either gender, fulfilling the inclusion criteria were planned for trabeculectomy with adjunctive use of Mitomycin-C (MMC) or Bevacizumab. Each group consisted of 53 patients (53 Eyes). The patients diagnosed with Primary Open Angle Glaucoma (POAG) with IOP ? 21 mm Hg and not controlled with topical anti-glaucoma medication were selected. Data were analyzed by using SPSS Version 22.0. Independent sample t test was used to check significance between two drugs. Paired sample t test was used to check significance of pre and post-operative IOP. Results: Mean age of patients was 56.67±7.34 years. Mean preoperative IOP was 31.51 ± 9.66 mm Hg in MMC group and 29.21 ± 7.69 mm Hg in Bevacizumab group. At first postoperative day, mean IOP after use of MMC was 14.75 ± 9.46 mm Hg and for Bevacizumab was 15.07 ± 6.47 mm Hg (p-value 0.001). Similarly, at one year follow-up, mean IOP for MMC group was 11.26 ± 2.31 mm Hg and for Bevacizumab was 11.73 ± 2.12 mm Hg(p-value 0.001). Conclusion: There was significant reduction in IOP in both MMC and Bevacizumab groups. However, the difference between the two groups was not statistically significant at mean follow-up of one year. Key Words: Primary Open Angle Glaucoma, Mitomycin–C, Intraocular Pressure, Bevacizumab, Trabeculectomy.

show abstract

“…40 Antitransforming growth factor β was tested but was no different to placebo. 41 The efficacy of other antifibrotics such as the anti-vascular endothelial growth factor agents [42][43][44][45] and the Ologen implant 46,47 need further study.…”

Section: Antifibroticsmentioning

confidence: 99%

The surgical management of glaucoma: A review

Lim

2022

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

After a long period of little change, glaucoma surgery has experienced a dramatic rise in the number of possible procedures in the last two decades. Glaucoma filtering surgeries with mitomycin C and glaucoma drainage devices remain the standard of surgical care. Other newer surgeries, some of which are minimally or microinvasive glaucoma surgeries, target existing trabecular outflow, enhance suprachoroidal outflow, create subconjunctival blebs, or reduce aqueous production. Some require the implantation of a device such as the iStent, Hydrus, Ex-PRESS, XEN and PRESERFLO, whilst others do not-Trabectome, Kahook dual blade, Ab interno canaloplasty, gonioscopy-assisted transluminal trabeculotomy, OMNI and excimer laser trabeculotomy. Others are a less destructive variation of an established procedure, such as micropulse transscleral cyclophotocoagulation, endoscopic cyclophotocoagulation and ultrasound cycloplasty. Cataract surgery alone can be a significant glaucoma operation. These older and newer glaucoma surgeries, their mechanism of action, efficacy and complications are the subject of this review.

show abstract

Intracameral Bevacizumab Versus Sub-Tenon’s Mitomycin C as Adjuncts to Trabeculectomy: 3-Year Results of a Prospective Randomized Study

Cited by 9 publications

References 24 publications

Intraocular Pressure Control after Trabeculectomy: A Comparison of Mitomycin C and Bevacizumab

Intraocular Pressure Control after Trabeculectomy: A Comparison of Mitomycin C and Bevacizumab

Intraocular Pressure Control after Trabeculectomy with Adjunctive Use of Mitomycin-C versus Bevacizumab: A Hospital Based Study

The surgical management of glaucoma: A review

Contact Info

Product

Resources

About